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A B S T R A C T
Background: The central role of prostate-speciﬁc antigen (PSA) testing in the diagnosis of prostate cancer
leads to the possibility that observational studies that report associations between risk factors and
prostate cancer could be affected by detection bias. This study aims to investigate whether reported risk
factors for prostate cancer are associated with PSA testing in a large middle-aged population-based
cohort in the UK.
Methods: The cross-sectional association between a wide range of sociodemographic, lifestyle, dietary
and health characteristics with PSA testing was examined in 212,039 men aged 40–69 years in UK
Biobank.
Results: A total of 62,022 (29%) men reported they had ever had a PSA test. A wide range of factors was
associated with a higher likelihood of PSA testing including age, height, education level, family history of
prostate cancer, black ethnic origin, not being in paid/self-employment, living with a wife or partner,
having had a vasectomy, being diagnosed with cancer or hypertension and having a high dietary intake of
cereal, cooked and salad/raw vegetables, fresh fruit and tea. Conversely, socioeconomic deprivation,
Asian ethnic origin, current smoking, low alcohol intake, high body-mass index, high coffee consumption
and being diagnosed with diabetes, heart disease or stroke were associated with a lower likelihood of PSA
testing.
Conclusions: A variety of sociodemographic, lifestyle and health-related characteristics are associated
with PSA testing, suggesting that observed associations of some of these traits with risk for prostate
cancer in epidemiological studies may be, at least partially, due to detection bias.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The only well-established lifestyle and demographic risk factors
for prostate cancer are advanced age, being of black ethnic origin
and having a family history of the disease. A wide range of other
sociodemographic, behavioural, dietary and health-related char-
acteristics have also been reported to be associated with increased
prostate cancer risk [1], although these ﬁndings are less well
established between studies and across populations. This
inconsistency may, in part, be due to detection bias if these
characteristics are also associated with the likelihood of havingAbbreviations: BMI, body mass index; CI, conﬁdence interval; OR, odds ratio;
PSA, prostate-speciﬁc antigen.
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1877-7821/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access artichad a prostate-speciﬁc antigen (PSA) test, which is a key part of the
diagnostic pathway for prostate cancer.
Enhanced detection through PSA testing largely explains the
increased incidence of prostate cancer over the last 20 years in
many countries [2,3]. In the UK, although PSA testing is not
currently recommended as a screening tool for prostate cancer [4],
it is widely performed in primary care, either as a frontline test for
men presenting with urinary tract/prostatic symptoms or as a free
test for men aged 50 years at the request of the patient [5]. The
aim of this study was to examine the associations between a wide
range of sociodemographic, lifestyle and health-related character-
istics and PSA testing in a large UK cohort without a routine
screening programme, with a particular focus on established or
possible risk factors for prostate cancer.
2. Material and methods
Participants were selected from UK Biobank, a large population-
based cohort study that recruited 502,649 men and women agedle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Logistic regression models investigating the association between baseline characteristics and having had a PSA test.
Characteristic Ever had a PSA test, No. (%) Model Aa Model Bb
No Yes OR (95% CI) p-value OR (95% CI) p-value
Age group (years)
40–44c 21,858 (95.5) 1,043 (4.6) 1 (Reference) 1 (Reference)
45–49 25,299 (91.4) 2,391 (8.6) 1.98 (1.84–2.13) 1.99 (1.85–2.15)
50–54 25,293 (81.3) 5,814 (18.7) 4.83 (4.51–5.17) 4.87 (4.54–5.21)
55–59 25,611 (68.6) 11,734 (31.4) 9.64 (9.03–10.3) 9.64 (9.01–10.3)
60–64 29,718 (58.6) 21,026 (41.4) 15.2 (14.2–16.2) 14.8 (13.8–15.8)
65–70d 22,238 (52.6) 20,014 (47.4) 20.0 (18.7–21.4) <0.001e 18.8 (17.6–20.2) <0.001e
Townsend deprivation score (quintiles)
One (most afﬂuent) 27,997 (66.1) 14,377 (33.9) 1 (Reference) 1 (Reference)
Two 28,870 (68.2) 13,472 (31.8) 0.92 (0.89–0.95) 0.93 (0.90–0.96)
Three 29,718 (70.2) 12,648 (29.9) 0.87 (0.84–0.90) 0.90 (0.87–0.92)
Four 30,752 (72.7) 11,579 (27.4) 0.84 (0.82–0.87) 0.88 (0.85–0.90)
Five (most deprived) 32,461 (76.7) 9,885 (23.3) 0.75 (0.72–0.77) <0.001e 0.84 (0.81–0.87) <0.001e
Education
No qualiﬁcations 24,503 (68.9) 11,037 (31.1) 1 (Reference) 1 (Reference)
CSE/O-Level/GCSE or
equivalent
21,540 (75.2) 7,111 (24.1) 1.16 (1.12–1.21) 1.08 (1.04–1.13)
AS/A-Level or equivalent 7,764 (72.6) 2,926 (27.4) 1.32 (1.25–1.39) 1.16 (1.10–1.23)
Higher education or other
professional qualiﬁcation, or
equivalent
93,415 (70.1) 39,858 (29.9) 1.42 (1.39–1.46) <0.001e 1.27 (1.23–1.31) <0.001e
Region
London 18,858 (67.6) 9,031 (32.38) 1 (Reference) 1 (Reference)
South-West 11,671 (65.4) 6,187 (34.7) 1.02 (0.97–1.06) 1.08 (1.03–1.13)
South-East 12,491 (69.1) 5,595 (30.9) 0.79 (0.75–0.82) 0.86 (0.82–0.90)
Wales 5,778 (65.0) 3,116 (35.0) 1.05 (1.00–1.11) 1.16 (1.10–1.23)
West Midlands 14,404 (71.7) 5,674 (28.3) 0.74 (0.71–0.77) 0.79 (0.75–0.82)
East Midlands 10,743 (74.8) 3,616 (25.2) 0.55 (0.53–0.58) 0.59 (0.56–0.63)
Yorkshire &
Humber
22,814 (72.6) 8,604 (27.4) 0.67 (0.64–0.69) 0.71 (0.68–0.74)
North-West 24,415 (71.7) 9,647 (28.3) 0.72 (0.70–0.75) 0.78 (0.75–0.82)
North-East 18,159 (74.0) 6,373 (26.0) 0.62 (0.60–0.65) 0.67 (0.64–0.70)
Scotland 10,684 (71.9) 4,179 (28.1) 0.74 (0.70–0.77) <0.001f 0.82 (0.78–0.86) <0.001f
Population density
Urban 128,703 (71.2) 52,093 (28.8) 1 (Reference) 1 (Reference)
Rural 19,457 (67.4) 9,404 (32.6) 1.01 (0.98–1.04) 0.52 1.01 (0.98–1.04) 0.49
Family history of prostate cancer
No 138,451 (71.9) 54,205 (28.1) 1 (Reference) 1 (Reference)
Brother or father 9,114 (57.8) 6,665 (42.2) 1.96 (1.89–2.03) 1.92 (1.86–2.00)
Brother and father 93 (27.4) 247 (72.7) 5.21 (4.06–6.69) <0.001e 5.32 (4.13–6.85) <0.001e
Ethnicity
White 140,176 (70.2) 59,570 (29.8) 1 (Reference) 1 (Reference)
Mixed background 805 (78.8) 217 (21.2) 1.11 (0.94–1.31) 1.07 (0.91–1.26)
Black 2,433 (77.8) 695 (22.2) 1.36 (1.24–1.50) 1.29 (1.17–1.41)
Asian 4,506 (82.9) 927 (17.1) 0.68 (0.63–0.73) 0.65 (0.60–0.71)
Other 1,460 (80.7) 350 (19.3) 0.97 (0.85–1.10) <0.0001f 0.95 (0.83–1.08) <0.001f
Employment
Paid/self-employment 100,556 (77.3) 29,459 (22.7) 1 (Reference) 1 (Reference)
Not in paid/self-employment 48,040 (60.0) 32,043 (40.0) 1.07 (1.04–1.09) <0.001 1.14 (1.11–1.16) <0.001
Lives with a wife or partner
No 26,801 (74.6) 9,140 (25.4) 1 (Reference) 1 (Reference)
Yes 112,178 (69.1) 50,170 (30.9) 1.23 (1.20–1.27) <0.001 1.21 (1.17–1.24) <0.001
Smoking
Never 75,246 (72.1) 29,084 (27.9) 1 (Reference) 1 (Reference)
Former 53,248 (66.1) 27,351 (33.9) 1.01 (0.99–1.03) 1.00 (0.98–1.02)
Current—Only occasionally 5,677 (76.2) 1,775 (23.8) 0.91 (0.85–0.96) 0.88 (0.83–0.94)
Current—On all or most
Days
15,298 (81.1) 3,567 (18.9) 0.65 (0.63–0.68) <0.001f 0.67 (0.64–0.70) <0.001f
Alcohol intake
Never 9,813 (73.8) 3,481 (26.2) 0.95 (0.91–0.99) 1.00 (0.95–1.04)
Special occasions only 11,304 (73.6) 4,064 (26.4) 0.92 (0.88–0.96) 0.94 (0.90–0.98)
One to three times a month 14,038 (74.7) 4,750 (25.3) 0.95 (0.91–0.99) 0.96 (0.92–1.00)
Once or twice a week 39,956 (72.7) 15,010 (27.3) 1 (Reference) 1 (Reference)
Three or four times a week 38,966 (70.1) 16,596 (29.9) 1.03 (1.00–1.06) 1.01 (0.98–1.03)
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Table 1 (Continued)
Characteristic Ever had a PSA test, No. (%) Model Aa Model Bb
No Yes OR (95% CI) p-value OR (95% CI) p-value
Daily or almost daily 35,775 (66.4) 18,086 (33.6) 1.06 (1.03–1.09) <0.001e 1.03 (1.00–1.06) <0.001e
BMI (kg/m2)
<18.5 399 (80.6) 96 (19.4) 0.65 (0.51–0.82) 0.74 (0.59–0.94)
18.5  25 37,654 (71.2) 15,234 (28.8) 1 (Reference) 1 (Reference)
25  30 72,875 (69.8) 31,479 (30.2) 1.01 (0.99–1.04) 1.00 (0.98–1.03)
30  35 29,364 (71.4) 11,791 (28.7) 0.95 (0.92–0.98) 0.95 (0.92–0.98)
35  40 6,660 (73.0) 2,464 (27.0) 0.91 (0.87–0.96) 0.92 (0.87–0.97)
40 2,078 (76.0) 655 (24.0) 0.86 (0.79–0.95) <0.001e 0.87 (0.79–0.96) <0.001e
Standing height (cm)
<175 64,890 (70.4) 27,342 (29.6) 1 (Reference) 1 (Reference)
175 180 41,620 (70.4) 17,520 (29.6) 1.10 (1.07–1.13) 1.07 (1.04–1.10)
180 42,714 (71.6) 16,921 (28.4) 1.20 (1.17–1.23) <0.001e 1.14 (1.11–1.17) <0.001e
Private healthcare
No 36,665 (72.6) 13,825 (27.4) 1 (Reference) 1 (Reference)
Yes 12,457 (60.1) 8,289 (40.0) 1.86 (1.80–1.94) <0.001 1.78 (1.71–1.85) <0.001
Vasectomy (self-report)
No 142,444 (70.8) 58,675 (29.2) 1 (Reference) 1 (Reference)
Yes 7,573 (69.4) 3,347 (30.7) 1.10 (1.05–1.15) <0.001 1.07 (1.02–1.12) 0.006
Cancer (cancer registry)g
No 143,158 (71.43) 57,270 (28.57) 1 (Reference) 1 (Reference)
Yes 6,859 (59.07) 4,752 (40.93) 1.22 (1.17–1.27) <0.001 1.22 (1.17–1.27) <0.001
Diabetes (self-report)
No 140,235 (70.9) 57,487 (29.1) 1 (Reference) 1 (Reference)
Yes 9,782 (68.3) 4,535 (31.7) 0.86 (0.83–0.89) <0.001 0.90 (0.87–0.94) <0.001
Heart disease (self-report)
No 138,464 (71.3) 55,727 (28.7) 1 (Reference) 1 (Reference)
Yes 11,553 (64.7) 6,295 (35.3) 0.91 (0.88–0.94) <0.001 0.95 (0.92–0.98) 0.003
Hypertension (self-report)
No 109,391 (73.3) 39,833 (26.7) 1 (Reference) 1 (Reference)
Yes 40,626 (64.7) 22,189 (35.3) 1.09 (1.06–1.11) <0.001 1.11 (1.09–1.14) <0.001
Stroke (self-report)
No 146,942 (70.9) 60,421 (29.1) 1 (Reference) 1 (Reference)
Yes 3,075 (65.8) 1,601 (34.2) 0.90 (0.84–0.96) 0.001 0.93 (0.87–0.99) 0.03
Abbreviations: BMI, body mass index; CI, conﬁdence interval; OR, odds ratio; PSA, prostate-speciﬁc antigen.
a Adjusted for age, Townsend deprivation score and education.
b Adjusted for age, Townsend deprivation score, education, region, family history of prostate cancer, ethnicity, employment, married/partner, smoking, alcohol intake, BMI,
standing height and private healthcare.
c Includes 4 participants who were <40 at baseline (minimum age = 38).
d Includes 1099 participants who >69 at baseline (maximum age = 73).
e Test for linear trend.
f Test for heterogeneity.
g Prostate cancer cases excluded.
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Biobank received ethical approval from the National Health Service
North West Centre for Research Ethics Committee (Ref: 11/NW/
0382). The assessment visit comprised electronic signed consent, a
touch-screen questionnaire, a brief computer-assisted interview,
physical measures, and collection of blood, urine and saliva
samples [6]. Of the 229,182 men recruited, data on PSA testing
were obtained from 228,715 (99.8%) men who responded to the
question ‘Have you ever had a blood test for prostate cancer (prostate
speciﬁc antigen or PSA test)?’. Of these, 216,289 (94.6%) responded
either yes or no; the remaining 12,426 participants who responded
with ‘Do not know’ or ‘Prefer not to answer’ were excluded from the
analysis. A further 4,250 men with prevalent prostate cancer
(based on cancer registry data), benign prostatic hyperplasia or
prostatitis (via self-report at recruitment) were excluded, resulting
in a ﬁnal sample size of 212,039 men.
Logistic regression models were used to investigate the
association between baseline characteristics and ever having
had a PSA test after adjustment for age, Townsend deprivationscore and education. Models were performed with additional
adjustment for region, family history of prostate cancer, ethnicity,
employment, living with a wife or partner, smoking status, alcohol
intake, body-mass index (BMI), standing height and private
healthcare. A test for linear trend was obtained by entering the
categorical variable into the model as a continuous variable; a test
for difference in odds ratios between categories of the exposures of
interest was obtained using the likelihood ratio test.
We also examined whether baseline characteristics of men who
undergo PSA testing because of prostate symptoms differ from
those of men who may request a PSA test as part of the National
Health Service prostate cancer risk management programme
available to men aged 50 years. Age at PSA testing was derived
from the question ‘How many years ago was your last test? which
was asked of men who responded that they had ever had a PSA test.
For all characteristics, a likelihood ratio was used to test for
heterogeneity between age groups (<50 vs. 50 years). For
characteristics for which there was signiﬁcant heterogeneity in the
association with PSA-testing by age group, logistic regression
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two-sided with statistical signiﬁcance set at <0.05. Statistical
analyses were performed using Stata/SE version 13.1 (StataCorp LP,
College Station, Texas).
3. Results
Of the 212,039 men included in the analyses, 62,022 (29%)
reported ever having had a PSA test. A wide range of sociodemo-
graphic, lifestyle and health-related characteristics were signiﬁ-
cantly associated with PSA testing (Table 1). Age was most strongly
associated with PSA testing (fully adjusted odds ratio [OR] for
65–70 years vs. 40–44 years = 18.8, 95% conﬁdence interval [CI]
17.6–20.2). Men who had a father or brother with prostate cancer
were twice as likely to have ever had a PSA test (OR = 1.92, 95% CI
1.86–2.00) compared to men with no family history; whilst men
who had a father and a brother with prostate cancer were more
than ﬁve times as likely (OR = 5.32, 95% CI 4.13–6.85, p-value for
linear trend <0.001). Men who were more highly educated, were of
black ethnic origin, not in paid/self-employment, living with a wife
or partner, had private healthcare, were taller, had a vasectomy or
who were diagnosed with (non-prostate) cancer or hypertension
were also more likely to have ever had a PSA test. Conversely, men
who lived in more socioeconomically deprived areas, were current
smokers, had a lower alcohol intake, a higher BMI or who had been
diagnosed with diabetes, heart disease or stroke were less likely toTable 2
Logistic regression models investigating the association between dietary characteristic
Characteristic Ever had a PSA test, No. (%) Model
No Yes OR (95
Cereal intake (bowls/week)
<1 28,776 (75.8) 9,173 (24.2) 1 (Ref
1–3 29,348 (74.4) 10,083 (25.6) 1.12 (1
4–6 39,569 (71.5) 15,775 (28.5) 1.22 (1
7 51,509 (65.8) 26,810 (34.2) 1.30 (1
Cooked vegetable intake (servings/day)
<1 9,964 (80.0) 2,490 (20.0) 1 (Ref
1 22,982 (75.4) 7,493 (24.6) 1.14 (1
2 46,753 (70.6) 19,469 (29.4) 1.22 (1
3 67,564 (68.0) 31,814 (32.0) 1.26 (1
Salad/raw vegetable intake (servings/day)
<1 29,130 (73.5) 10,488 (26.5) 1 (Ref
1 47,673 (70.9) 19,579 (29.1) 1.22 (1
2 33,370 (69.5) 14,632 (30.5) 1.16 (1
3 37,197 (69.3) 16,509 (30.7) 1.17 (1
Fresh fruit intake (servings/day)
<1 20,181 (77.8) 5,748 (22.2) 1 (Ref
1 45,844 (71.6) 18,157 (28.4) 1.20 (1
2 39,460 (69.3) 17,482 (30.7) 1.29 (1
3 43,648 (68.1) 20,415 (31.87) 1.37 (1
Tea consumption (cups/day)
<1 27,722 (75.3) 9,080 (24.7) 1 (Ref
1–2 35,466 (70.8) 14,655 (29.2) 1.17 (1
3–4 41,345 (68.3) 19,175 (31.7) 1.19 (1
5 45,126 (70.3) 19,024 (29.7) 1.12 (1
Coffee consumption (cups/day)
<1 41,932 (72.4) 15,984 (27.6) 1 (Ref
1–2 54,126 (67.8) 25,656 (32.2) 1.09 (1
3 53,509 (72.5) 20,275 (27.5) 0.94 (0
Abbreviations: CI, conﬁdence interval; OR, odds ratio; PSA, prostate-speciﬁc antigen.
a Adjusted for age, Townsend deprivation score and education.
b Adjusted for age, Townsend deprivation score, education, region, family history of pro
standing height and private healthcare.
c Test for linear trend.have had a PSA test. There was also regional variation, with PSA
testing being least common in the East Midlands and North East
England and most common in Wales and South West England.
Mutual adjustment for these factors made little difference to the
observed associations.
Several dietary characteristics were also associated with PSA
testing (Table 2), with a higher intake of cereal, cooked
vegetables, salad/raw vegetables, fresh fruit and tea consumption
associated with a higher likelihood of PSA testing, whereas a
higher coffee consumption was associated with a lower likelihood
of PSA testing.
The associations of several sociodemographic and lifestyle
factors with PSA testing differed by age at testing, with generally
stronger associations found in men aged 50 years compared to
men aged <50 years (Table 3).
4. Discussion
We examined the relationship between a wide range of putative
risk factors for prostate cancer, including sociodemographic,
lifestyle, dietary and health characteristics, and the likelihood of
having had a PSA test in a population without a routine
PSA-screening programme. These ﬁndings are important because
of the central role of PSA testing in the diagnosis of prostate cancer,
which leads to the possibility that associations reported betweens and having had a PSA test.
 Aa Model Bb
% CI) p-value OR (95% CI) p-value
erence) 1 (Reference)
.09–1.16) 1.11 (1.08–1.15)
.19–1.26) 1.18 (1.14–1.22)
.26–1.34) <0.001c 1.26 (1.22–1.30) <0.001c
erence) 1 (Reference)
.08–1.21) 1.07 (1.01–1.13)
.16–1.28) 1.11 (1.05–1.17)
.20–1.32) <0.001c 1.14 (1.09–1.20) <0.001c
erence) 1 (Reference)
.09–1.16) 1.07 (1.04–1.10)
.12–1.20) 1.10 (1.06–1.13)
.13–1.21) <0.001c 1.11 (1.07–1.14) <0.001c
erence) 1 (Reference)
.15–1.24) 1.14 (1.09–1.18)
.24–1.34) 1.21 (1.17–1.26)
.32–1.42) <0.001c 1.30 (1.25–1.35) <0.001c
erence) 1 (Reference)
.13–1.21) 1.14 (1.10–1.17)
.15–1.23) 1.16 (1.12–1.20)
.09–1.16) <0.001c 1.13 (1.09–1.16) <0.001c
erence) 1 (Reference)
.06–1.12) 1.05 (1.02–1.07)
.92–0.97) <0.001c 0.93 (0.91–0.96) <0.001c
state cancer, ethnicity, employment, married/partner, smoking, alcohol intake, BMI,
Table 3
The association between characteristics and having had a PSA test stratiﬁed by age at testing.a,b
Characteristic <50 years old at time of PSA test (n = 7106) 50 years old at time of PSA test (n = 53,112) p-value for difference
by age at PSA testc
OR (95% CI) p-value OR (95% CI) p-value
Townsend deprivation score (quintiles)
One (most afﬂuent) 1 (Reference) 1 (Reference)
Two 0.89 (0.83–0.95) 0.94 (0.90–0.97)
Three 0.89 (0.83–0.95) 0.90 (0.87–0.93)
Four 0.90 (0.84–0.97) 0.87 (0.84–0.90)
Five (most deprived) 0.93 (0.86–1.00) 0.08d 0.83 (0.80–0.86) <0.001d <0.001
Region
London 1 (Reference) 1 (Reference)
South-West 0.87 (0.79–0.96) 1.16 (1.10–1.22)
South-East 0.84 (0.75–0.93) 0.88 (0.83–0.93)
Wales 0.98 (0.87–1.11) 1.25 (1.17–1.33)
West Midlands 0.81 (0.74–0.89) 0.80 (0.76–0.84)
East Midlands 0.57 (0.51–0.64) 0.61 (0.58–0.65)
Yorkshire & Humber 0.70 (0.64–0.76) 0.73 (0.69–0.76)
North-West 0.74 (0.68–0.80) 0.80 (0.77–0.84)
North-East 0.68 (0.62–0.75) 0.68 (0.65–0.72)
Scotland 0.71 (0.64–0.79) <0.001e 0.86 (0.81–0.91) <0.001e <0.001
Family history of prostate cancer
No 1 (Reference) 1 (Reference)
Brother or father 2.35 (2.21–2.51) 1.76 (1.69–1.83)
Brother and father 4.39 (2.64–7.31) <0.001d 5.03 (3.87–6.54) <0.001d <0.001
Smoking
Never 1 (Reference) 1 (Reference)
Former 1.03 (0.98–1.08) 0.99 (0.97–1.01)
Current—Only
occasionally
0.99 (0.89–1.11) 0.84 (0.79–0.90)
Current—On all or most
days
0.78 (0.72–0.85) <0.001e 0.64 (0.61–0.67) <0.001e <0.001
Alcohol intake
Never 1.07 (0.97–1.18) 0.98 (0.94–1.04)
Special occasions only 1.03 (0.94–1.13) 0.92 (0.88–0.97)
One to three times a
month
0.96 (0.88–1.04) 0.96 (0.91–1.00)
Once or twice a week 1 (Reference) 1 (Reference)
Three or four times a
week
0.96 (0.91–1.02) 1.01 (0.98–1.04)
Daily or almost daily 0.93 (0.88–1.00) 0.004d 1.03 (1.00–1.06) <0.001d 0.02
BMI (kg/m2)
<18.5 0.85 (0.53–1.36) 0.70 (0.54–0.91)
18.5  25 1 (Reference) 1 (Reference)
25  30 0.97 (0.92–1.02) 1.00 (0.97–1.03)
30  35 0.94 (0.88–1.01) 0.94 (0.91–0.97)
35  40 0.98 (0.87–1.09) 0.91 (0.86–0.96)
40 1.08 (0.91–1.30) 0.44d 0.84 (0.75–0.93) <0.001d 0.001
Heart disease (self-report)
No 1 (Reference) 1 (Reference)
Yes 1.16 (1.06–1.27) 0.001 0.94 (0.91–0.97) 0.001 0.01
Stroke (self-report)
No 1 (Reference) 1 (Reference)
Yes 1.17 (0.99–1.38) 0.06 0.92 (0.86–0.98) 0.01 0.04
Fresh fruit intake (servings/day)
<1 1 (Reference) 1 (Reference)
1 1.06 (0.98–1.14) 1.15 (1.10–1.19)
2 1.06 (0.98–1.14) 1.24 (1.19–1.29)
3 1.18 (1.10–1.27) <0.001d 1.31 (1.26–1.36) <0.001d 0.04
Abbreviations: BMI, body mass index; CI, conﬁdence interval; OR, odds ratio; PSA, prostate-speciﬁc antigen.
a Adjusted for age, Townsend deprivation score, education, region, family history of prostate cancer, ethnicity, employment, married/partner, smoking, alcohol intake, BMI,
standing height and private healthcare.
b Includes only those characteristics that showed statistically signiﬁcant heterogeneity by age group.
c Heterogeneity in odds ratios between subgroups deﬁned by age at PSA testing adjusted for age, Townsend deprivation score, education, family history of prostate cancer,
ethnicity, employment, smoking, BMI and longstanding illness.
d Test for linear trend.
e Test for difference.
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affected by detection bias (i.e. factors that are associated with men
choosing to undergo PSA testing will, in turn, be associated with
increased prostate cancer incidence).
In this large population-based cohort of middle-aged UK men,
PSA testing was independently associated with age, a family
history of prostate cancer, higher education, living with a wife or
partner, private healthcare, height, having had a vasectomy, being
diagnosed with cancer or hypertension and consuming a healthy
diet. In contrast, socioeconomic deprivation, current smoking,
having a lower alcohol intake, a higher BMI, a higher coffee
consumption and being diagnosed with diabetes, heart disease or
stroke were associated with less PSA testing. Our ﬁndings are
consistent with a small number of studies based on general
practitioner records conducted in the UK that found that men who
are older [7–10], less socioeconomically deprived [7–10] and who
live in southern UK regions [8] are more likely to undergo PSA
testing, whereas men of Asian ethnic origin [7] are less likely to
undergo PSA testing. We also found that men of black ethnic origin
were more likely to have had a PSA test, independent of other
factors such as family history and education status.
Many lifestyle characteristics reported here as being associated
with PSA testing have also been associated with an increased risk
of prostate cancer incidence, including family history [11], black
ethnic origin [12] and height [13]. Conversely, factors associated
with a lower rate of PSA testing have been associated with a lower
risk of prostate cancer, such as obesity [14], diabetes [15], being of
Asian ethnic origin [16] and smoking [17]. This suggests that the
magnitude of associations observed with risk of total prostate
cancer for established risk factors such as black ethnic origin and
family history might be exaggerated in recent studies, whereas less
well-established associations (such as those between dietary
factors and prostate cancer risk), might be due to detection bias.
This study has several strengths. Due to the breadth and depth of
information available in UK Biobank, we were able to explore a wide
range of sociodemographic, lifestyle and health characteristics in
relation to PSA testing, including characteristics previously identi-
ﬁed as risk factors for prostate cancer. Our ﬁnding that socioeco-
nomic deprivation, current smoking, higher BMI and a diagnosis of
heart disease or stroke were more strongly associated with a lower
likelihood of PSA testing in older men (who are more likely to choose
to have a PSA test) compared withyounger men (who are more likely
to have a PSA test due to symptoms) [5], suggests that, among older
men, the decision to request a PSA test is highly determined by
lifestyle and sociodemographic factors in this population. This may
have implications in interpreting the relationships between lifestyle
factors and subsequent prostate cancer incidence.
However, this study also has several limitations. UK Biobank is a
self-selected sample, with 29% of men reporting they had ever had
a PSA test, which is substantially higher than a previous study in
the UK general population that estimated the prevalence of PSA
testing in asymptomatic men aged 45–89 years to be about 6% in
the same time period [8]. Nonetheless, the ﬁndings from the
current study do highlight the potential role of detection bias in
epidemiological studies when investigating risk factors for
prostate cancer in most Western populations where PSA testing
is correlated with health-seeking behaviour. PSA testing was
determined by self-report which may be subject to misclassiﬁca-
tion bias if, for example, men were unaware of having had a PSA
test or had forgotten about it. Furthermore, the study did not
collect information on the timing, frequency, reason or the
outcome of each PSA test. Future linkage of UK Biobank data to
primary care records will help us to address some of these
limitations and to expand the analyses to the exploration of factors
associated with PSA testing over time.5. Conclusions
This population-based study shows the associations between a
wide range of sociodemographic, lifestyle, dietary and health
characteristics and the likelihood of PSA testing in a large UK
cohort. These results indicate that it is important to consider the
role of detection bias in epidemiological studies investigating risk
factors for prostate cancer.
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